Gastrointestinal Cancer

>

Latest News

Novel Therapy Yields Anti-Tumor Activity in KRAS G12C–Mutated CRC
Novel Therapy Yields Anti-Tumor Activity in KRAS G12C–Mutated CRC

May 31st 2025

As a single agent or in combination, MK-1084 showed promising efficacy and safety results for patients with KRAS G12C–mutated CRC.

Emergent alteration patterns were similarly diverse across treatment arms in the phase 3 CodeBreaK 300 study.
Genomic Alterations May Cause Resistance to Sotorasib KRAS G12C+ CRC Combo

May 31st 2025

Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC
Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

May 31st 2025

Anlotinib/chemotherapy showed comparable efficacy vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer.
Anlotinib Shows Noninferiority to Bevacizumab in RAS/BRAF Wild-Type mCRC

May 31st 2025

ctDNA-Informed Treatment Doesn’t Impact RFS in Stage III Colon Cancer
ctDNA-Informed Treatment Doesn’t Impact RFS in Stage III Colon Cancer

May 31st 2025

Latest CME Events & Activities

Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®

View More

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

View More

Go To PER in Chicago

May 30, 2025 - June 3, 2025

Register Now!

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

View More

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

View More

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

View More

<1
...
5253545556